Imaging neuroinflammation in frontotemporal dementia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates neuroinflammation in patients with frontotemporal dementia (FTD) using hybrid PET/MRI imaging techniques. It aims to assess the relationship between neuroinflammation, cerebral perfusion, and brain structure in FTD patients. Participants will undergo neurocognitive assessments and imaging with the PET ligand FEPPA, which targets activated microglia, a marker of neuroinflammation. The study will also explore differential patterns of neuroinflammation across various clinical and molecular subtypes of FTD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients diagnosed with a probable Frontotemporal Dementia or neurologically healthy control participants with no history of neurological problems
2. Study partner is available who has frequent contact with the subject and can accompany the subject to all clinic visits for the duration of the protocol.
3. Visual and auditory acuity adequate for neuropsychological testing
4. Good general health with no diseases expected to interfere with the study.
5. Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal, surgically sterile or practicing an effective form of family planning
6. Willing to participate in a longitudinal imaging study at 12 months.
7. Willing to undergo MRI (3Tesla)/ PET scan (with FEPPA ligand) and no medical contraindications to MRI.

Exclusion Criteria:

1. Any significant neurologic disease other than suspected Frontotemporal Dementia that would better account for symptoms (i.e. frontal lobe stroke).
2. Screening/baseline MRI scans with evidence of infection, infarction, or other focal lesions. Subjects with multiple lacunes are excluded.
3. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body that may preclude MRI participation as per MRI screening form.
4. Major depression, bipolar disorder as described in DSM-IV within the past 1 year. Psychotic features, agitation or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol.
5. History of schizophrenia (DSM IV criteria).
6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
7. Clinically significant abnormalities in B12, or thyroid function tests that might interfere with the study.
8. Investigational agents are prohibited one month prior to entry and for the duration of the trial.
9. Exclusion for FEPPA: Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the subject in any given year would exceed the limits of annual and total dose commitment set forth. The current regulation for radiation dose to patient volunteers and health control volunteers are contained within Health Canada's recently amended (June 19, 2012) Regulations Amending the Food and Drug Regulations (Positron-emitting Radiopharmaceuticals). Limitations for effective total body dose is 50 mSv (C.03.305 (c)) which has been increased from the previous values of 20 mSv (Table 1 in INFO-0491).
10. Exclusion Criteria for controls undergoing arterial line placement: Absent pulse, Thromboangiitis obliterans (Buerger disease), Burns over the cannulation site, Inadequate circulation to the extremity, Raynaud syndrome, Anticoagulation therapy, Atherosclerosis of upper extremity vessels, Coagulopathy, inadequate collateral flow, Infection at the cannulation site, Previous surgery in the area, Synthetic vascular graft.

Where it's running

• Parkwood Institute
  London, Ontario, Canada Recruiting

Study contacts

• Study coordinator: S Jesso, BA
• Email: cognitiveneurology@sjhc.london.on.ca
• Phone: 519-646-6000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes

  This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.

  Recruiting Center for Eye Research Australia · Melbourne, Victoria · NCT07545473

• ARO-MAPT-SC in healthy adults and people with early Alzheimer's disease

  This trial will test whether ARO-MAPT-SC is safe, tolerable, and produces the expected drug levels and biomarker effects in healthy adults and people with early Alzheimer's disease.

  Recruiting at 4 sites Phase 1/2 Arrowhead Pharmaceuticals · East York, Ontario and 3 other locations · NCT07221344

• STELLA-FTD: Telehealth support program for family caregivers of frontotemporal degeneration

  This program will see if eight weekly live video group sessions help family caregivers of people with frontotemporal degeneration manage challenging behaviors and connect with community and peer resources.

  Recruiting Oregon Health and Science University · Portland, Oregon · NCT06613204

• Using vortioxetine to improve mood and cognition in patients with frontotemporal dementia

  This study is testing if a medication called vortioxetine can help improve mood and thinking skills in people with early-stage behavioral variant Frontotemporal Dementia.

  Recruiting Phase 2 Johns Hopkins University · Baltimore, Maryland · NCT06604520

• Predicting disease progression in dementia using biomarkers and modeling

  This study is trying to create a tool that helps predict how dementia will progress in people with mild cognitive impairment and different types of dementia, like Alzheimer's and Lewy Body Disease, by looking at brain scans, body fluids, and mental tests.

  Recruiting University Health Network, Toronto · North York, Ontario and 3 other locations · NCT06529744

• Comparing protein patterns in skin biopsies of neurodegenerative diseases

  This study is trying to see if the patterns of certain proteins in skin samples can help doctors better understand and diagnose different neurodegenerative diseases like Alzheimer's, Parkinson's, and frontotemporal dementia.

  Recruiting Universidad Autonoma de San Luis Potosí · San Luis Potosí City · NCT06528964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.